Clinical trials
Prostate cancer clinical trials
Cancer of the prostate gland, one of the most common cancers in men. We’re tracking 1,212 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07483658Recruiting
Salvage pelvic radiotherapy: 20 vs 25 sessions for recurring prostate cancer
This trial compares two schedules of pelvic radiotherapy for men whose prostate cancer has returned after surgery. Both schedules aim to control the cancer with fewer visits for one of them.
Gatineau, QuebecAges 18 years+ - NCT06657131Recruiting
PSMA PET scan for prostate cancer recurrence
This trial looks at how well a special PET scan (called PSMA PET) can find prostate cancer that has come back after treatment. It uses a radioactive tracer to spot cancer cells. Your doctor may already have ordered this scan as part of your regular care.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07477626RecruitingPhase 3
Radiation therapy after prostate surgery for advanced prostate cancer
This study tests whether radiation therapy to the pelvis after prostate removal helps men whose cancer was found in nearby lymph nodes. The goal is to prevent cancer from coming back and improve survival.
Dongguan, GuangdongAges 18 years+ - NCT07468708RecruitingEarly Phase 1
Testing a new imaging agent for prostate cancer
This trial tests a new radioactive tracer called ⁶⁸Ga-FC516 to see how well it works for imaging prostate cancer. It may help doctors find and monitor prostate cancer more accurately.
Guangzhou, GuangdongAges 18 years+ - NCT07468903Recruiting
Focal radiation for prostate cancer with HDR brachytherapy
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
Los Angeles, CaliforniaAges 40 years+ - NCT06468332Recruiting
AI learning from MRI and tissue to improve prostate cancer care
This study uses artificial intelligence to look at your MRI scans, tissue samples, and medical records to learn more about prostate cancer and find better ways to treat it. You may join if you've had prostate removal surgery or have advanced prostate cancer.
NovaraAges 18–80 - NCT07439913Enrolling by invitation
Predicting cancer return and bladder control after robot prostate surgery
This study looks at factors that can predict whether prostate cancer will come back in the 10 years after robot-assisted prostate removal surgery, and how well bladder control (urinary continence) recovers. It helps doctors understand which patients might do better long-term.
Banská BystricaAges Any age - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07426094RecruitingPhase 2/Phase 3
Boosting radiation for prostate cancer in lymph nodes
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07426055RecruitingPhase 2/Phase 3
Prostate cancer radiation boost comparison study
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06449781RecruitingPhase 2
177Lu-PSMA after surgery or radiation for high-risk prostate cancer
This study tests a new treatment called 177Lu-PSMA given after standard therapy (surgery or radiation) to see if it can prevent prostate cancer from coming back. It is for patients with high or very high-risk prostate cancer that hasn't spread yet.
GliwiceAges 18 years+ - NCT07422597Recruiting
MRI or risk calculator for suspected prostate cancer
This trial compares using an upfront MRI versus a risk calculator to decide who needs a prostate biopsy. It may help men with suspected localized prostate cancer avoid unnecessary biopsies.
LevangerAges 50–75 - NCT06612047Recruiting
Comparing high-field and ultra-high-field MRI for prostate cancer diagnosis
This study compares two types of MRI scans – one at 3.0 Tesla and one at 5.0 Tesla – to see which is better at finding prostate cancer. If you are scheduled for a prostate biopsy, you may be asked to get both scans to help improve detection.
Hefei, AnhuiAges 18 years+ - NCT06737588Recruiting
Better MRI scanning for prostate cancer detection
This study tests if a special MRI measurement (ADC) can improve how well a standard MRI finds prostate cancer. If you have a suspicious MRI and are scheduled for a biopsy, this might help better understand your results.
Hefei, AnhuiAges 18 years+ - NCT06783127Recruiting
Olaparib for BRCA-related prostate cancer
This trial studies how well olaparib works for men with metastatic castration-resistant prostate cancer that has a BRCA mutation. It looks at results from real-world use, not a controlled study.
NaplesAges Any age - NCT06820333Recruiting
PSMA PET scan for newly diagnosed prostate cancer
This trial looks at how well a special scan called PSMA PET/CT can help find the spread of prostate cancer when it is first diagnosed. You may be able to join if your doctor has already recommended this scan for you.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07407608Recruiting
Radiation therapy for unfavorable prostate cancer
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
Monza, MBAges 18–90 - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07407283RecruitingPhase 1/Phase 2
Study of SHR-4394 combination therapy for prostate cancer
This trial tests a new drug called SHR-4394 combined with standard hormone therapy for men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination can help control the cancer.
Chengdu, SichuanAges 18–85 - NCT07398690Recruiting
MRI-guided approach for prostate cancer diagnosis
This trial tests if using MRI and a blood test called PHI can help decide who needs a prostate biopsy. It aims to avoid unnecessary biopsies while still catching cancer early.
SeoulAges 20 years+ - NCT07393867RecruitingPhase 2
PSMA-guided radiation boost for prostate cancer
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
Boston, MassachusettsAges 18 years+ - NCT06242119Recruiting
Testing a new PET scanner prototype
This study is testing a new type of PET scanner (called J-PET) to see if it works as well as current PET/CT machines. If you are already scheduled for a whole-body PET/CT scan, participating would mean your scan is done with this experimental scanner instead.
KrakowAges 18 years+ - NCT07387263Recruiting
Digital tool for genetic testing in cancer care
This study tests a digital tool that helps cancer doctors offer genetic testing to more patients. If you've already had genetic testing started by your oncologist, you may be able to join.
Toronto, OntarioAges 18 years+ - NCT07363382RecruitingPhase 1/Phase 2
Testing GRPR PET Scan for Prostate Cancer
This study tests a new imaging method (GRPR PET) to help better see and stage prostate cancer. If you have prostate cancer, this scan may give doctors more detail about where the cancer is located.
Fuzhou, FujianAges 18–90
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer?
- Yes. Clin2 currently lists 1,212 recruiting prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.